Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation

Bucan,Vesna; Choi,Claudia  Y.U.; Lazaridis,Andrea; Vogt,Peter  M.; Reimers,Kerstin

doi:10.3892/ol.2011.285

Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation

Authors:
- Vesna Bucan
- Claudia Y.U. Choi
- Andrea Lazaridis
- Peter M. Vogt
- Kerstin Reimers
View Affiliations

Affiliations: Department of Plastic, Hand and Reconstructive Surgery, Medical School Hanover, D-30659 Hanover, Germany
Published online on: March 21, 2011 https://doi.org/10.3892/ol.2011.285
Pages: 419-422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lifeguard (LFG), an anti-apoptotic protein with high expression rates in breast cancer cells, has been identified as a molecule that inhibits death mediated by Fas. The molecular function of LFG and its regulation in the carcinogenesis of human breast and sarcoma cells, however, remains to be elucidated. In the present study, we investigated the ability of LFG expression to inhibit apoptosis induced by the alkyl-phospholipid perifosine. Results showed that LFG was able to be downregulated in selected sarcoma and breast cancer cell lines characterized by high endogenous LFG expression. A decreased LFG expression led to enhanced sensitivity to treatment with an agonistic Fas antibody or treatment with perifosine. Taken together, our findings indicate the role of LFG as an anti-apoptotic protein and provide further evidence of the potential of LFG as a target for the development of novel therapeutic strategies.

View Figures

View References

1	Hu L, Smith TF and Goldberger G: LFG: A candidate apoptosis regulatory gene family. Apoptosis. 14:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI
2	Somia NV, Schmitt MJ, Vetter DE, et al: LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci USA. 96:12667–12672. 1999. View Article : Google Scholar : PubMed/NCBI
3	Beier CP, Wischhusen J, Gleichmann M, et al: FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci. 25:6765–6774. 2005. View Article : Google Scholar : PubMed/NCBI
4	Reimers K, Choi CY, Mau-Thek E, et al: Sequence analysis shows that Lifeguard belongs to a new evolutionarily conserved cytoprotective family. Int J Mol Med. 18:729–734. 2006.PubMed/NCBI
5	Bucan V, Reimers K, Choi CY, et al: The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues. Cell Mol Biol Lett. 15:296–310. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bucan V, Adili MY, Choi CY, et al: Transactivation of lifeguard (LFG) by Akt-/LEF-1 pathway in MCF-7 and MDA-MB 231 human breast cancer cells. Apoptosis. 15:814–821. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kondapaka SB, Singh SS, Dasmahapatra GP, et al: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2:1093–1103. 2003.PubMed/NCBI
8	Patel V, Lahusen T, Sy T, et al: Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res. 62:1401–1409. 2002.
9	Gajate C and Mollinedo F: Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood. 109:711–719. 2007. View Article : Google Scholar
10	Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al: In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res. 16:2046–2054. 2010. View Article : Google Scholar : PubMed/NCBI
11	Van der Luit AH, Vink SR, Klarenbeek JB, et al: A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol Cancer Ther. 6:2337–2345. 2007.PubMed/NCBI
12	Bailey HH, Mahoney MR, Ettinger DS, et al: Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 107:2462–2467. 2006. View Article : Google Scholar : PubMed/NCBI
13	Knowling M, Blackstein M, Tozer R, et al: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 24:435–439. 2006. View Article : Google Scholar
14	Leighl NB, Dent S, Clemons M, et al: A Phase II study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat. 108:87–92. 2008. View Article : Google Scholar : PubMed/NCBI
15	Munoz-Martinez F, Torres C, Castanys S, et al: The anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells. Biochim Biophys Acta. 1778:530–540. 2008. View Article : Google Scholar
16	Vink SR, van der Luit AH, Klarenbeek JB, et al: Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem Pharmacol. 74:1456–1465. 2007. View Article : Google Scholar
17	Mravljak J, Zeisig R and Pecar S: Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs. J Med Chem. 48:6393–6399. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ruiter GA, Zerp SF, Bartelink H, et al: Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs. 14:167–173. 2003. View Article : Google Scholar : PubMed/NCBI
19	Vink SR, van Blitterswijk WJ, Schellens JH, et al: Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev. 33:191–202. 2007. View Article : Google Scholar : PubMed/NCBI
20	Duggan BJ, Maxwell P, Kelly JD, et al: The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol. 166:1098–1105. 2001. View Article : Google Scholar : PubMed/NCBI
21	Li F, Srinivasan A, Wang Y, et al: Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem. 272:30299–30305. 1997. View Article : Google Scholar : PubMed/NCBI
22	Strasberg RM, Zangemeister-Wittke U and Rieber M: p53- independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide. Clin Cancer Res. 7:1446–1451. 2001.PubMed/NCBI
23	Tortora G, Caputo R, Damiano V, et al: Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res. 7:2537–2544. 2001.
24	Zangemeister-Wittke U, Leech SH, Olie RA, et al: A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 6:2547–2555. 2000.